Vaxcyte (PCVX) executive compensation, 2026 proxy

Grant E. Pickering, Chief Executive Officer, was paid $14.5M in 2025, down 64% from $39.6M the year before. The CEO-to-median-employee pay ratio was 48:1, on median employee pay of $303,873.

Filed
April 23, 2026
Annual meeting
June 15, 2026
Pay year
2025
Named executives
5
CEO total pay
$14.5M-64% vs prior year
CEO to median employee
48:1median $303,873
CEO pay in equity
90%$13M in awards
Prior say-on-pay support
64%of votes cast
CEO Target Bonus
$900,000Expressed as 900,000 target dollars
Public Offering Proceeds
$632.5MCompleted in February 2026
Bonus Payout Percentage
105%Of target for named executive officers

How Pickering was paid

$14.5M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.

Salary6%Stock awards30%Option awards60%Non-equity incentive4%All other compensation0%

Named executive officers

ExecutiveTotal
Grant E. PickeringChief Executive Officer$14,458,937
Andrew GuggenhimePresident and Chief Financial Officer$6,072,939
Jim WassilExecutive Vice President and Chief Operating Officer$5,809,971
Mikhail EydelmanSenior Vice President, General Counsel and Corporate Secretary$4,005,935
Harp DhaliwalChief Technical Operations Officer$3,764,679

What changed and why

  • $14.5MChief Executive Officer total compensation was $14,458,937 for 2025.
  • 105%Named executive officers received an annual bonus payout of 105% of target for 2025.
  • No one-time or off-cycle awards were granted in 2025 following stockholder feedback.
  • 50%Stockholders holding approximately 50% of outstanding stock were met with during enhanced outreach.

About this page

Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.